Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 4 · newest first

  1. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus TrialBlood · 2023
  2. Tenofovir-Induced Fanconi Syndrome Presenting with Life-Threatening Hypokalemia: Review of the Literature and Recommendations for Early DetectionJournal of Clinical Medicine · 2023
  3. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentClinical Lymphoma Myeloma & Leukemia · 2023
  4. Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma PatientsBlood · 2023
  5. Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma PatientsBlood · 2023
  6. Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)Blood · 2023
  7. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2023
  8. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2023
  9. Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent TherapiesHemaSphere · 2023
  10. Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialCancers · 2023
  11. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron EraDiseases · 2023
  12. MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical ChallengesHemato · 2023
  13. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trialFrontiers in Hematology · 2023
  14. Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and DegradationInternational Journal of Molecular Sciences · 2023
  15. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantationLeukemia & lymphoma/Leukemia and lymphoma · 2023
  16. Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON StudyClinical Lymphoma Myeloma & Leukemia · 2023
  17. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab‐based therapyBritish Journal of Haematology · 2023
  18. EPH/Ephrin Signaling in Normal Hematopoiesis and Hematologic Malignancies: Deciphering Their Intricate Role and Unraveling Possible New Therapeutic TargetsCancers · 2023
  19. S198: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma NetworkHemaSphere · 2023
  20. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple MyelomaInternational Journal of Molecular Sciences · 2023
  21. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyJournal of Clinical Oncology · 2023
  22. Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian CancerCancers · 2023
  23. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE studyAmerican Journal of Hematology · 2023
  24. EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2023
  25. Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case reportOncology Letters · 2023
  26. SARS-CoV-2 Infection in Patients With Waldenström’s Macroglobulinemia: A Multicenter International Cohort StudyHemaSphere · 2023
  27. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant SettingThe Breast Journal · 2023
  28. Prevalence of MGCS Among Patients With Monoclonal GammopathiesHemaSphere · 2023
  29. Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of OmicronOpen Forum Infectious Diseases · 2023
  30. Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapiesEuropean Journal Of Haematology · 2023
  31. Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the LiteratureMedical Sciences · 2023
  32. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studyBlood Advances · 2023
  33. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyBlood Cancer Journal · 2023
  34. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON StudiesClinical Lymphoma Myeloma & Leukemia · 2023
  35. Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal GammopathiesJournal of Molecular Diagnostics · 2023
  36. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myelomaJournal of Translational Medicine · 2023
  37. Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 StudyClinical Lymphoma Myeloma & Leukemia · 2023
  38. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B diseaseHematological Oncology · 2023
  39. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective StudyViruses · 2023
  40. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study groupAmerican Journal of Hematology · 2023
  41. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 studyCancer Medicine · 2023
  42. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathyBlood Cancer Journal · 2023
  43. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort studyThe Lancet Haematology · 2023
  44. XBB .1.5 neutralizing antibodies upon bivalent COVID ‐19 vaccination are similar to XBB but lower than BQ .1.1American Journal of Hematology · 2023
  45. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's MacroglobulinemiaJournal of Clinical Oncology · 2023
  46. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management StrategiesJACC CardioOncology · 2023
  47. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018Blood Cancer Journal · 2023
  48. What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literatureGynecologic Oncology Reports · 2023
  49. Monoclonal Gammopathy of Thrombotic SignificanceCancers · 2023
  50. A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaBlood Cancer Journal · 2023